JUBLPHARMAJubilant Pharmova Ltd.
Jubilant Pharmova Q2 FY27 Results: Consolidated Net Profit ₹31.00 Crore on Total Income of ₹2,384 Crore
- Earnings
- pharmaceuticals

Jubilant Pharmova (NSE: JUBLPHARMA) reported consolidated total income of ₹2,384 crore and net profit of ₹31 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹69 crore and net profit of ₹8 crore, it said in a filing on 13 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹2,384 crore, up 20.7% YoY and 6.0% QoQ
- Net profit and EPS: ₹31 crore, down 74.1% YoY and 45.0% QoQ; basic EPS ₹1.97
- Finance costs: ₹58 crore, up 16.3% YoY and 7.7% QoQ
Standalone
The company on its own, without its subsidiaries
- Total income: ₹69 crore, up 3.3% YoY and QoQ
- Net profit and EPS: ₹8 crore against a loss of ₹6 crore a year earlier; basic EPS ₹0.48
- Exceptional items: None shown for the quarter; ₹8.7 crore in the year ended 31 Mar 2026
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 2,384 | 1,976 | +20.7% | 2,249 | +6.0% | |
| Revenue from operations | 2,370 | 1,966 | +20.5% | 2,229 | +6.3% |
| Other income | 14 | 10 | +46.9% | 20 | -27.6% |
| 31 | 120 | -74.1% | 56 | -45.0% | |
| Profit before tax | 62 | 190 | -67.6% | 86 | -28.6% |
| Finance costs | 58 | 50 | +16.3% | 54 | +7.7% |
| Depreciation | 135 | 105 | +28.6% | 127 | +5.9% |
| Tax expense | 31 | 70 | -56.4% | 30 | +2.3% |
| Net profit margin | 1.30% | 6.07% | -4.77 pp | 2.51% | -1.21 pp |
| EPS, basic (₹) | 1.97 | 7.59 | -74.0% | 3.57 | -44.8% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Income grew faster than profit. Total income rose 20.7% YoY, but net profit fell 74.1%, and profit before tax fell 67.6% to ₹62 crore from ₹190 crore. Revenue from operations rose 20.5% and other income rose 46.9%, though other income is only 0.6% of total income.
Finance costs of ₹58 crore are 2.4% of total income, and depreciation rose 28.6% YoY to ₹135 crore. The filing gives no reason for the fall in profit before tax.
The segment note shows Radiopharma revenue of ₹1,009.3 crore in the quarter against ₹897.1 crore a year earlier. The consolidated statement shows exceptional items of ₹59.2 crore in the year ended 31 Mar 2026, and none is shown for this quarter in the table.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 69 | 67 | +3.3% | 67 | +3.3% | |
| Revenue from operations | 69 | 66 | +3.2% | 67 | +2.1% |
| Other income | 1 | 1 | +12.5% | 0 | +800.0% |
| 8 | -6 | n/a | 7 | +4.1% | |
| Profit before tax | 10 | 9 | +21.2% | 10 | +5.1% |
| Finance costs | 1 | 3 | -60.0% | 1 | +11.1% |
| Depreciation | 1 | 2 | -18.8% | 1 | -7.1% |
| Tax expense | 3 | n/a | n/a | 3 | +8.0% |
| Net profit margin | 10.95% | -9.52% | +20.47 pp | 10.86% | +0.09 pp |
| EPS, basic (₹) | 0.48 | -0.40 | n/a | 0.46 | +4.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit moved back into positive territory. Net profit was ₹8 crore against a loss of ₹6 crore in the year-ago quarter, and rose 4.1% QoQ, faster than total income's 3.3% rise.
Finance costs fell to ₹1 crore from ₹3 crore a year earlier, and other income is 1.4% of total income. Tax expense of ₹3 crore is 26.2% of profit before tax; the year-ago quarter's tax expense is not shown in the statement.
Inference
The filing reports the Board's approval on 12 Oct 2026 of up to 80,000 unsecured and secured non-convertible debentures aggregating ₹800 crore on a private placement basis, and their allotment of unsecured NCDs for ₹800 crore on 5 Nov 2026. The company also paid dividends of ₹79.4 crore standalone and ₹78.9 crore consolidated in the half year. The filing does not say what the NCD proceeds will fund, or why the year-ago quarter's standalone tax and the fall in consolidated profit before tax occurred.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.